Optimal Timing of Complete Revascularization in Patients With ST-Elevation Myocardial Infarction and Multivessel...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Complete revascularization (CR) is recommended for ST-segment elevation myocardial infarction (STEMI) with multivessel disease (MVD).
• The optimal timing for CR—immediate versus staged—remains debated.
• This meta-analysis evaluates randomized controlled trials (RCTs) comparing immediate CR to staged CR in STEMI patients with MVD.

Purpose of the Study:

• To compare the efficacy and safety of immediate versus staged CR in patients with STEMI and MVD.
• To determine if immediate CR reduces major adverse cardiovascular events (MACE) compared to staged CR.
• To assess secondary outcomes including mortality, recurrent myocardial infarction, and procedural complications.

Main Methods:

• Systematic search of MEDLINE, Scopus, and Cochrane databases for relevant RCTs.
• Included 11 RCTs with 4,472 patients, mean follow-up of 18.5 months.
• Primary outcome was MACE; secondary outcomes included mortality, MI, revascularization, stent thrombosis, stroke, bleeding, and nephropathy.

Main Results:

• Immediate CR did not significantly reduce MACE compared to staged CR (RR 0.92 [0.73, 1.17]).
• No significant differences were observed in all-cause mortality, cardiovascular mortality, recurrent MI, unplanned revascularization, or stent thrombosis.
• Safety endpoints, including stroke, major bleeding, and acute nephropathy, were comparable between immediate and staged CR groups.

Conclusions:

• Immediate and staged CR demonstrate similar efficacy and safety profiles in STEMI patients with MVD.
• Findings are consistent despite heterogeneity in study designs and patient populations.
• Optimal timing of CR should consider anatomic complexity, physiology, logistics, and patient-specific factors.